📄 [Communiqué de presse] – MaaT Pharma annonce que le premier patient aux États-Unis a été traité avec MaaT013 à l’hôpital City of Hope dans le cadre du programme d’accès élargi pour la maladie aiguë du greffon contre l’hôte (aGvH). Ce traitement à usage compassionnel a été

📄 [Press release] – MaaT Pharma is proud to announce positive Phase 3 results evaluating MaaT013 in treating acute Graft-versus-Host Disease with gastrointestinal involvement (#aGvHD). Topline Data highlights: ✅ Primary endpoint met: significant GI-ORR at Day 28 of 62%,

📅 [#EVENT] – Join Alexandre Kiss, Europe Medical Advisor for Oncology and Hematology at MaaT Pharma, at the 17th “Journée Greffe” of Institut Paoli-Calmettes (IPC), taking place on January 25, in Marseille, France. This annual event has become a key moment to reflect on and shape the

The phase 3 ARES study, evaluating MaaT013 in patients with acute GVHD with gastrointestinal involvement after treatment refractoriness to steroids or ruxolitinib, met its primary end point of GI-ORR at day 28. Mohamad Mohty #hematology #oncology onclive.com/view/ares-tria…

💡 What does recent data tell us about the potential for targeting #aGvHD through the #microbiome? ICYMI, learn more about our Phase 3 results from Professor Mohamad Mohty:

📰 – Proud to keep sharing the positive Phase 3 data in #aGvHD through media coverage, this time featured in Scrip, Citeline Commercial! Thanks to Alaric DeArment for reporting on our milestones, including the Phase 3 data and our EMA filing. 👉 Read the full article: insights.citeline.com/scrip/therapeu…

📝 A new study published in the Journal of Hematology found that post-HSCT viral infection was associated with increased incidence of aGvHD in pediatric patients. More news: gvhdhub.com #GvHD #MedNews #MedEd

📰 MaaT Pharma in CancerNetwork® ! We’re thrilled to see our latest achievement covered in CancerNetwork® with Roman Fabbricatore highlighting our phase 3 ARES results, confirming MaaT013’s positive benefit/risk profile and its potential as a third-line treatment for GI-aGvHD.

📢 Annonce positive pour MaaT Pharma ! Nous sommes fiers de présenter de nouvelles données précliniques prometteuses à l’AACR pour MaaT034 visant à améliorer les réponses des patients aux immunothérapies. Les principaux résultats démontrent que MaaT034 : ✅ S’implante

🎥 #EBMT2025 – An insightful interview with Prof. Florent Malard and Prof. Riccardo Masetti on the impact of the microbiome in HSCT outcomes! Prof. Malard discusses how a diverse microbiome correlates with improved survival rates and reduced risk of GvHD, while also mentioning

📰 MaaT Pharma in BioTuesdays! We’re proud to see our CEO, Hervé Affagard Herve Affagard, highlight our pioneering work in Microbiome Ecosystem Therapies, to transform cancer care and improve patient outcomes. A big thank you to Melane Sampson for this great feature in BioTuesdays!

📰 MaaT Pharma in Le Point! We’re proud to be featured in the special issue “Ces projets qui façonnent la santé du futur” (Shaping the future of healthcare), written by Valérie Peiffer and Raphaël Ruffier-Fossoul, highlighting our pioneering work in restoring gut microbiome

📰 MaaT Pharma in OncLive.com! Thrilled to see our latest announcement covered by Ashling Wahner, highlighting MaaT033’s safety in allo-HSCT patients and the DSMB’s recommendation to continue the PHOEBUS trial. You can read the article here: onclive.com/view/investiga… #DSMB #Safety

📰 More Great Media Coverage for our positive safety update for MaaT033 in Phase 2b trial! We’re proud to see Investir Les Echos cover the DSMB’s favorable interim safety assessment in our ongoing study in allo-HSCT patients. 👉 Read the article here: investir.lesechos.fr/actu-des-valeu…

📰 #Media - We’re proud to be featured for the first time in Het Financieele Dagblad FD Nieuws, a leading Dutch financial daily newspaper, In an article highlighting the thriving life sciences ecosystem in Lyon, the piece includes our recent clinical milestones, our

Excited to be at #AACR25 and proud to present new promising preclinical data on MaaT034 for the first time! Bastien Laperrousaz, our head of preclinical development, is looking forward to connecting and sharing more about this innovative program!

📰 [#PressRelease] – We’re thrilled to announce that our Phase 3 results evaluating Xervyteg® (MaaT013) in acute Graft-versus-Host Disease have been selected for oral presentation at American Society of Hematology (ASH) Congress 2025. Key highlights: ✅ Oral

📄 [#PressRelease] - MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update ✅€10.5M upfront payment received from our exclusive license & distribution agreement with Clinigen, paving the way for potential European access to Xervyteg®

📰 #PressRelease -MaaT Pharma will present four abstracts, including the final results of the pivotal Phase 3 ARES trial evaluating MaaT013 in gastrointestinal aGvHD during an oral presentation scheduled in the Presidential Plenary Session. 🔹 Posters: • CHRONOS – Real‑world

📰 [#CommuniquéDePresse] - MaaT Pharma annonce quatre présentations lors du 52ᵉ Congrès Annuel de l’EBMT et met en lumière le symposium organisé par Clinigen sur la prise en charge de la GvHD aiguë. 🔹 Présentation orale par le Professeur Florent Malard– Session plénière